4CMenB journey to the 10-year anniversary and beyond

4CMenB journey to the 10-year anniversary and beyond

The 4-component meningococcal serogroup B (MenB) vaccine, 4CMenB, the first broadly protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 countries worldwide. Real-world evidence (RWE) from the last decade confirms its effectiveness and impact, with infant immuniza...

Full description

Saved in:
Bibliographic Details
Main Authors: Véronique Abitbol, Federico Martinón-Torres, Muhamed-Kheir Taha, Terry Nolan, Alessandro Muzzi, Stefania Bambini, Ray Borrow, Daniela Toneatto, Laura Serino, Rino Rappuoli, Mariagrazia Pizza
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
4CMenB
Bexsero
cross-protection
effectiveness
impact
Neisseria meningitidis
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2357924
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2024.2357924

Similar Items